Search research articles
Contact Us
Filters
Showing results (51-60 of 110) with videos related to
Page
of 11
Sort By:
Breast (Edinburgh, Scotland)
|
October 19, 2006
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study
Mario Campone, Pierre Fumoleau, Patrice Viens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2011
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer
Erica L Mayer, Jean-Francois Baurain, Joseph Sparano, et al.
Future Oncology (London, England)
|
August 12, 2015
Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial
Séverine Guiu, Céline Charon-Barra, Déwi Vernerey, et al.
Breast Cancer Research and Treatment
|
March 16, 2010
Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy
Sylvain Ladoire, Laurent Arnould, Grégoire Mignot, et al.
Bulletin Du Cancer
|
August 2, 2021
[Adapting to the SARS-CoV2 pandemic: Experience of the Curie Institute]
Elisabeth Lucchi-Angellier, Jean-Christophe Mino, Alexis Burnod, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 12, 2015
Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study
Xavier Pivot, Thomas Suter, Jean Marc Nabholtz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2012
Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors
Nicolas Isambert, Gilles Freyer, Sylvie Zanetta, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 8, 2013
¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations
Alexandre Cochet, Inna Dygai-Cochet, Jean-Marc Riedinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2015
Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Olivier Humbert, Jean-Marc Riedinger, Céline Charon-Barra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2007
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification
Laurent Arnould, Patrick Arveux, Jerome Couturier, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 110) with videos related to
Sort By:
Page
of 11
Breast (Edinburgh, Scotland)
|
October 19, 2006
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study
Mario Campone, Pierre Fumoleau, Patrice Viens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2011
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer
Erica L Mayer, Jean-Francois Baurain, Joseph Sparano, et al.
Future Oncology (London, England)
|
August 12, 2015
Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial
Séverine Guiu, Céline Charon-Barra, Déwi Vernerey, et al.
Breast Cancer Research and Treatment
|
March 16, 2010
Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy
Sylvain Ladoire, Laurent Arnould, Grégoire Mignot, et al.
Bulletin Du Cancer
|
August 2, 2021
[Adapting to the SARS-CoV2 pandemic: Experience of the Curie Institute]
Elisabeth Lucchi-Angellier, Jean-Christophe Mino, Alexis Burnod, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 12, 2015
Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study
Xavier Pivot, Thomas Suter, Jean Marc Nabholtz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2012
Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors
Nicolas Isambert, Gilles Freyer, Sylvie Zanetta, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 8, 2013
¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations
Alexandre Cochet, Inna Dygai-Cochet, Jean-Marc Riedinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2015
Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Olivier Humbert, Jean-Marc Riedinger, Céline Charon-Barra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2007
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification
Laurent Arnould, Patrick Arveux, Jerome Couturier, et al.
Page
of 11